Findings
There are significant risks associated with connected sensor technologies that exceed current evaluation capabilities, including validation, security practices, data rights and governance, utility and usability, and economic feasibility.
Existing evaluation frameworks are inadequate for the unique challenges posed by digital health technologies.
The regulatory environment for digital specimens is not well-established, leading to ambiguity in oversight.

Recommendations
Develop a systematic and standardized evaluation framework for connected sensor technologies.
Implement a connected sensor technology label to improve transparency and decision-making.
Encourage innovation and modern regulatory oversight through updated guidelines.
Address the evolving distinction between regulated and unregulated digital health technologies.
Enhance communication infrastructure to make information more accessible to stakeholders.

Regulatory Considerations
The regulatory environment for digital health technologies is evolving, with a need for modern oversight.
There is ambiguity in the regulation of digital specimens, requiring clearer guidelines.
The FDA has issued guidances to encourage innovation and efficient oversight.

Findings
High-quality data must be complete, accurate, timely, and fit for purpose, ensuring reliability for RWE generation.
Effective governance is critical to ensure transparency, ethical standards, and stakeholder engagement in managing RWD.
Data capture challenges include standardization, provenance tracking, and interoperability, particularly for EHR-based data.
Data curation is iterative and involves organizing, assessing, and preparing raw data to meet study-specific needs.
The maturity model identifies five stages of organizational data capabilities, emphasizing consistency, completeness, and automation.

Recommendations
Implement robust governance frameworks to address transparency, stakeholder engagement, and ethical considerations in RWD use.
Focus on improving data capture at the point of care through standardization and semantic interoperability.
Use common data models and validated extraction-transformation-loading (ETL) processes to enhance data consistency and reliability.
Prioritize iterative data curation practices, supported by metadata and provenance tracking, to improve fitness for use over time.
Leverage the NESTcc Data Quality Maturity Model to benchmark and enhance organizational capabilities in RWD management.

Regulatory Considerations
Ensure compliance with patient privacy laws such as HIPAA and GDPR, especially when linking data across sources.
Align data capture and curation practices with FDA guidance for RWE generation and medical device evaluation.
Establish clear data use agreements to protect patient data while enabling analysis for regulatory and research purposes.
Document data transformations, including metadata and provenance, to support reproducibility and transparency in regulatory submissions.
Embrace standard terminologies and data dictionaries to facilitate interoperability and regulatory acceptance.

Findings
Successful deployment of digital clinical measures requires a shared foundation of standardized methodologies, terminology, and best practices.
The selection of digital measures must prioritize patient-centered outcomes and align with meaningful aspects of health.
Technology validation processes, including the Verification, Analytical Validation, and Clinical Validation (V3) framework, are crucial to ensuring data accuracy and reliability.
Interoperability, data security, and governance remain key challenges for digital health technologies in both research and clinical applications.
Case studies demonstrate the real-world utility of digital clinical measures in clinical research, patient care, and public health initiatives.

Recommendations
Stakeholders should follow a structured, stepwise approach to selecting and validating digital clinical measures, starting with identifying meaningful health aspects.
Digital health tools must undergo rigorous verification and validation to ensure they are fit-for-purpose and meet clinical and regulatory standards.
Patient engagement should be integrated into every stage of digital measure development to ensure the relevance and usability of selected endpoints.
Regulatory and payer engagement should occur early in the process to streamline market access and reimbursement pathways.
Organizations should adopt a proactive approach to data privacy, security, and governance, ensuring compliance with regulations such as HIPAA and GDPR.

Regulatory Considerations
The FDA and other regulatory bodies emphasize the need for clinical validation of digital measures before they can be used as primary endpoints in trials.
Standardization of digital health technologies is critical to regulatory approval, requiring alignment with frameworks such as HL7 and ISO standards.
Data security and privacy regulations must be strictly adhered to, particularly in decentralized clinical trials where remote monitoring is used.
Digital endpoint validation must include real-world evidence (RWE) to support regulatory decision-making and post-market surveillance.
Organizations must consider the evolving regulatory landscape for AI-driven health technologies, ensuring compliance with best practices for algorithmic transparency and bias mitigation.